✦ LIBER ✦

Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma

✍ Scribed by Takashi Watanabe; Shoji Terui; Kuniaki Itoh; Takashi Terauchi; Tadahiko Igarashi; Noriko Usubuchi; Masanobu Nakata; Shigeru Nawano; Naohiro Sekiguchi; Shigeru Kusumoto; Kazuki Tanimoto; Yukio Kobayashi; Keigo Endo; Taku Seriu; Masaki Hayashi; Kensei Tobinai

Book ID: 108583561
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 122 KB
Volume: 96
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2005.00120.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Japanese phase II study of 90Y-ibritumom

Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

✍ Kensei Tobinai; Takashi Watanabe; Michinori Ogura; Yasuo Morishima; Tomomitsu Ho 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Phase I study of LY2469298, an Fc-engine

Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma

✍ Kensei Tobinai; Michinori Ogura; Yukio Kobayashi; Toshiki Uchida; Takashi Watana 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

Tandem high-dose therapy in relapsed and

Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with131I-anti-CD20 antibody and stem cell rescue

✍ Karin Hohloch; Carsten Oliver Sahlmann; Vijai J. Lakhani; Gerald Wulf; Bertram G 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 233 KB